Published in Head Neck on November 01, 2009
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol (2010) 3.37
Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res (2011) 1.70
Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol (2013) 1.63
Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol (2011) 1.61
mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res (2012) 1.32
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer (2013) 1.28
Nitric oxide and cancer: a review. World J Surg Oncol (2013) 1.22
Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol (2013) 1.21
The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol (2012) 1.13
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12
Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer (2013) 1.10
Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. Oral Oncol (2014) 1.08
Screening for high risk human papilloma virus (HR-HPV) subtypes, among Sudanese patients with oral lesions. Int J Clin Exp Med (2013) 1.06
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma - a prospective cohort and interobserver variability study. Histopathology (2011) 1.03
Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010. Oral Oncol (2011) 1.01
Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol (2011) 0.98
Combined P16 and human papillomavirus testing predicts head and neck cancer survival. Int J Cancer (2014) 0.98
Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol (2009) 0.97
Spindle cell carcinomas of the head and neck rarely harbor transcriptionally-active human papillomavirus. Head Neck Pathol (2013) 0.96
The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res (2013) 0.95
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer. Cancer Res (2012) 0.94
Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment. Otolaryngol Clin North Am (2013) 0.94
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Arch (2014) 0.91
Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes. Am J Surg Pathol (2014) 0.89
Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue. Oral Oncol (2014) 0.89
The sinonasal tract: another potential "hot spot" for carcinomas with transcriptionally-active human papillomavirus. Head Neck Pathol (2013) 0.89
Lack of association of cadherin expression and histopathologic type, metastasis, or patient outcome in oropharyngeal squamous cell carcinoma: a tissue microarray study. Head Neck Pathol (2011) 0.89
Interaction between Chronic Inflammation and Oral HPV Infection in the Etiology of Head and Neck Cancers. Int J Otolaryngol (2012) 0.87
Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers. Am J Surg Pathol (2012) 0.86
Mucoepidermoid carcinoma does not harbor transcriptionally active high risk human papillomavirus even in the absence of the MAML2 translocation. Head Neck Pathol (2014) 0.83
The immune response in HPV(+) oropharyngeal cancer. Oncoimmunology (2014) 0.83
Is human papillomavirus involved in laryngeal neuroendocrine carcinoma? Eur Arch Otorhinolaryngol (2012) 0.82
Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy. PLoS One (2013) 0.81
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2015) 0.81
Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Mod Pathol (2015) 0.81
Joint disease mapping of cervical and male oropharyngeal cancer incidence in blacks and whites in South Carolina. Spat Spatiotemporal Epidemiol (2010) 0.80
Oral lichen planus in thai patients has a low prevalence of human papillomavirus. ISRN Dent (2013) 0.78
Biomarkers of head and neck cancer, tools or a gordian knot? Int J Clin Exp Med (2015) 0.78
Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol (2012) 0.78
Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget (2015) 0.77
Update on role of chemotherapy in head and neck squamous cell cancer. Indian J Surg Oncol (2010) 0.77
Expression of human papillomavirus-related proteins and its clinical implication in tonsillar squamous cell carcinoma. Korean J Pathol (2012) 0.77
Small biopsy specimens reliably indicate p16 expression status of oropharyngeal squamous cell carcinoma. Head Neck Pathol (2011) 0.77
Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns. Head Neck (2012) 0.77
Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer. J Otolaryngol Head Neck Surg (2013) 0.77
Introduction: Human papillomavirus in head and neck cancer: an update for 2012 with a focus on controversial topics. Head Neck Pathol (2012) 0.75
Immunohistochemical study on ADAM33 in sinonasal inverted papillomas and squamous cell carcinomas of the larynx. Arch Med Sci (2016) 0.75
Human papillomavirus infection a favorable prognostic factor in laryngeal squamous cell carcinoma is associated with the expression of proliferating cell nuclear antigen. Pak J Med Sci (2013) 0.75
Sinonasal adenoid cystic carcinoma: Treatment outcomes and association with human papillomavirus. Head Neck (2017) 0.75
Human papillomavirus and head and neck carcinomas: focus on evidence in the babel of published data. Acta Otorhinolaryngol Ital (2016) 0.75
Smoking cessation care among patients with head and neck cancer: a systematic review. BMJ Open (2016) 0.75
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck (2017) 0.75
Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) (2015) 0.75
Influence of smoking history on imaging characteristics among patients with human papillomavirus-positive oropharyngeal cancer: a blinded matched-pair analysis. J Comput Assist Tomogr (2014) 0.75
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. Head Neck (2016) 0.75
A Prospective Study of the Lymphedema and Fibrosis Continuum in Patients with Head and Neck Cancer. Lymphat Res Biol (2016) 0.75
The impact of sexual behavior on oral HPV infections in young unvaccinated adults. Clin Oral Investig (2015) 0.75
p16, HPV, and Cetuximab: What Is the Evidence? Oncologist (2017) 0.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Prevalence of oral HPV infection in the United States, 2009-2010. JAMA (2012) 6.02
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis (2009) 5.24
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol (2008) 4.39
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer (2008) 3.16
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis (2004) 3.04
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer (2008) 2.67
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Burden of cervical cancer in the United States, 1998-2003. Cancer (2008) 2.57
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res (2009) 2.51
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst (2009) 2.45
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat (2007) 2.41
Genital human papillomavirus infection in men. Lancet Infect Dis (2006) 2.39
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
New directions in the systemic treatment of metastatic thyroid cancer. Oncology (Williston Park) (2009) 2.14
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck (2012) 2.07
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol (2007) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99
Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol (2012) 1.96
Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis (2010) 1.85
Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.85
Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol (2012) 1.81
Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol (2012) 1.81